[lcus_masonry_article] Case Study: A Foundry R&D Group Shortens Material Discovery with a Ranked Database and a Top Candidate A foundry’s materials R&D group was under pressure to identify a next-generation semiconductor material that could meet performance, thermal, and cost targets. Internal efforts had produced a long list of candidates but no clear “lead” with full […]
content by LCUS
Case Study – A Mid-Tier Pharma Uses a 300-Disease Package to Prioritize and Out-License
[lcus_masonry_article] Case Study: A Mid-Tier Pharma Uses a 300-Disease Package to Prioritize and Out-License A mid-tier pharmaceutical company wanted to expand its early pipeline without running 300 separate discovery programs. They were interested in a single, structured research package that covered many indications with a consistent methodology—compound analysis, synthesis methods, biological mechanism documentation—so they could […]
Case Study – A Pharma Partner Licenses the Parkinson’s Cure Discovery Package for Pipeline
[lcus_masonry_article] Case Study: A Pharma Partner Licenses the Parkinson’s Cure Discovery Package for Pipeline A pharmaceutical company with a strong CNS pipeline was looking for a cure-focused Parkinson’s asset—not another symptomatic therapy—that came with a clear discovery report, methodology, compound analysis, and synthesis pathways. They had the development and regulatory capacity; they needed a defined […]
Case Study – A Biotech Evaluates the Alzheimer’s Cure Discovery for a Multi-Mechanism Program
[lcus_masonry_article] Case Study: A Biotech Evaluates the Alzheimer’s Cure Discovery for a Multi-Mechanism Program A biotech focused on neurodegenerative disease wanted to expand beyond amyloid-only approaches. They were interested in a research package that targeted Alzheimer’s through multiple mechanisms—amyloid, tau, neuroinflammation, neuronal regeneration—with a consistent methodology and documentation suitable for partnership and regulatory planning. They […]
Case Study – A Diabetes-Focused Partner Uses the Cure Discovery to De-Risk Lead Selection
[lcus_masonry_article] Case Study: A Diabetes-Focused Partner Uses the Cure Discovery to De-Risk Lead Selection A company with a diabetes and metabolic pipeline was looking for cure-focused compounds—not another glucose management asset—with validated discovery scores, synthesis methods, and scientific evidence aligned with known mechanisms (e.g. zinc–amino acid complexes, insulin signaling). They had development capacity; they needed […]
Case Study – An Aerospace Developer Evaluates Zero-Emission Supersonic Propulsion for a Next-Gen Platform
[lcus_masonry_article] Case Study: An Aerospace Developer Evaluates Zero-Emission Supersonic Propulsion for a Next-Gen Platform An aerospace technology developer was exploring zero-emission propulsion for a next-generation supersonic platform. They had the integration and certification experience; they needed a complete technology handoff—engineering blueprints, technical specifications, implementation resources—that they could evaluate and then take to partners or regulators. […]
Case Study – A Research Lab Evaluates AutoPhi FUTURE for a Sovereign Quantum Pilot
[lcus_masonry_article] Case Study: A Research Lab Evaluates AutoPhi FUTURE for a Sovereign Quantum Pilot A North American semiconductor and quantum research consortium had a mandate: explore an original computing architecture for a sovereign high-performance and quantum pilot, without dependency on a single incumbent ISA or foundry. They had 14 months to shortlist options and produce […]
Case Study – A Formulation Team Uses Software-First Chemistry Before Committing to Hardware
[lcus_masonry_article] Case Study: A Formulation Team Uses Software-First Chemistry Before Committing to Hardware A European biotech with a small formulation group needed to scale recipe design and synthesis planning without buying another benchtop reactor before they knew their lead candidates. They had PubChem and in-house data; what they lacked was a single environment where recipes […]